Multidrug resistance of acute leukemia and a strategy to overcome it
- PMID: 11197207
Multidrug resistance of acute leukemia and a strategy to overcome it
Abstract
A representative cause of multidrug resistance (MDR) is expression of the MDR gene (mdr1) and its product P-glycoprotein (P-gp). The function of P-gp is thought to be the extrusion of anticancer drugs from the cell against a concentration gradient. In acute myelogenous leukemia (AML), P-gp expression in leukemic blast cells at initial presentation has been reported to be 20% to 40%. The remission rate of acute leukemia patients is significantly lower in P-gp+ patients than in P-gp- patients. A significantly shorter survival and relapse-free survival in P-gp+ AML patients compared with P-gp- patients has been reported. Intracellular daunorubicin/Rhodamine123 content in P-gp+ leukemic blast cells is significantly lower than in P-gp- leukemic blast cells. By using a leukemic blast colony assay, lowered sensitivity to the anticancer drug was revealed not only in leukemic blast cells but also in leukemic progenitors. One method to overcome MDR with a possibility of clinical application is to use drugs that interfere with the function of P-gp. The addition of MS-209 in vitro as an MDR-reversing agent significantly enhanced the intracellular daunorubicin/Rhodamine 123 accumulation and the retention of P-gp+ leukemic blast cells to a level similar to that of P-gp- blast cells. Recent clinical trials using MDR-reversing agents have demonstrated some encouraging results in P-gp+ patients but not in P-gp- patients.
Similar articles
-
The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.Semin Hematol. 1997 Oct;34(4 Suppl 5):25-33. Semin Hematol. 1997. PMID: 9408958
-
Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.Haematologica. 2000 Jul;85(7):711-21. Haematologica. 2000. PMID: 10897123
-
Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.Cancer Chemother Pharmacol. 2002 May;49(5):391-7. doi: 10.1007/s00280-001-0411-5. Epub 2002 Feb 14. Cancer Chemother Pharmacol. 2002. PMID: 11976833
-
Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.Methods Find Exp Clin Pharmacol. 2007 Nov;29(9):607-17. doi: 10.1358/mf.2007.29.9.1139054. Methods Find Exp Clin Pharmacol. 2007. PMID: 18193112 Review.
-
Multidrug resistance in haematological malignancies.J Intern Med. 2000 May;247(5):521-34. J Intern Med. 2000. PMID: 10809991 Review.
Cited by
-
L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation.Int J Hematol. 2001 Dec;74(4):447-50. doi: 10.1007/BF02982090. Int J Hematol. 2001. PMID: 11794702
-
Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.Br J Clin Pharmacol. 2011 Apr;71(4):514-21. doi: 10.1111/j.1365-2125.2010.03894.x. Br J Clin Pharmacol. 2011. PMID: 21204910 Free PMC article.
-
Complete remission induced by gemtuzumab ozogamicin in a Jehovah's Witness patient with acute myelogenous leukemia.Int J Hematol. 2007 Jun;85(5):418-20. doi: 10.1532/IJH97.07018. Int J Hematol. 2007. PMID: 17562618
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous